Abstract:
Th1 cells are involved in Th1-mediated autoimmune disorders whereas Th2 cells are involved in Th2-medaited autoimmune disorders. Polyacetylenic glucosides can be identified using a T cell platform in a bioactivity-guided manner. The function of these compounds can be in vivo confirmed using different types of autoimmune disease mice.
Fields of Application:
1. Ploacetylenic glucosides can prevent Th1-mediated autoimmune diseases such as autoimmune diabetes. 2. This platform can be used as a screening platform for autoimmune disease drugs
Advantages when compared to the existing technologies:
1. These two platforms can screen out bioactive compounds for treatment of autoimmuned diseases. 2. Polyacetylenic glucosides can be served as botanical therapeuticals or alternative/supplementary medications for Th1-mediated autoimmune diseases.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you
IP Status:US pending TW pending
